Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.
According to Acasti Pharma Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.00. At the end of 2022 the company had a P/S ratio of 0.00.
Year | P/S ratio |
---|---|
2023 | 0.00 |
2022 | 0.00 |
2021 | 0.00 |
2020 | 363.14 |
2019 | 0.00 |
2018 | 0.00 |
2017 | 0.00 |
2016 | 0.00 |
2015 | 778.92 |
2014 | 337.41 |
2013 | 263.37 |
2012 | 241.66 |
2011 | 863.78 |
2010 | 313.83 |
2009 | 0.00 |